http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Polymorphisms in cancer-related pathway genes and lung cancer
Lee, Shin Yup,Kang, Hyo-Gyoung,Choi, Jin Eun,Jung, Deuk Kju,Lee, Won Kee,Lee, Hyun Chul,Lee, So Yeon,Yoo, Seung Soo,Lee, Jaehee,Seok, Yangki,Lee, Eung Bae,Cha, Seung Ick,Cho, Sukki,Kim, Chang Ho,Lee, European Respiratory Society 2016 The European respiratory journal Vol.48 No.4
<P>We evaluated the associations between potentially functional variants in a comprehensive list of cancer-related genes and lung cancer in a Korean population.</P><P>A total of 1969 potentially functional single nucleotide polymorphisms (SNPs) of 1151 genes involved in carcinogenesis were evaluated using an Affymetrix custom-made GeneChip in 610 nonsmall cell lung cancer patients and 610 healthy controls. A replication study was conducted in an independent set of 490 cases and 486 controls. 68 SNPs were significantly associated with lung cancer in the discovery set and tested for replication.</P><P>Among the 68 SNPs, three SNPs (corepressor interacting with RBPJ 1 (<I>CIR1</I>) rs13009079T>C, ribonucleotide reductase M1 (<I>RRM1</I>) rs1465952T>C and solute carrier family 38, member 4 (<I>SLC38A4</I>) rs2429467C>T) consistantly showed significant associations with lung cancer in the replication study. In combined analysis, adjusted odds ratio for <I>CIR1</I> rs13009079T>C, <I>RRM1</I> rs1465952T>C and <I>SLC38A4</I> rs2429467C>T were 0.69, 0.71 and 0.73, respectively (p=4×10<SUP>−5</SUP>, 0.01 and 0.001, respectively) under the dominant model. The relative mRNA expression level of <I>CIR1</I> was significantly associated with rs13009079T>C genotypes in normal lung tissues (ptrend=0.03).</P><P>These results suggest that the three SNPs, particularly <I>CIR1</I> rs13009079T>C, may play a role in the pathogenesis of lung cancer.</P>
Lee, Jaehee,Lim, Jae Kwang,Lee, So Yeon,Yoo, Seung Soo,Lee, Shin Yup,Cha, Seung Ick,Park, Jae Yong,Kim, Chang Ho Elsevier 2016 The American journal of the medical sciences Vol.351 No.2
<P>Objectives: Tuberculous pleural effusion (TPE) is generally characterized by lymphocytic exudative effusion, either free flowing or loculated. However, patients can also have neutrophilic loculated TPE, although little data are available concerning the incidence and characteristics of this form of TPE. It is important to differentiate between neutrophilic loculated TPE and complicated parapneumonic effusion (PPE), which also shows neutrophilic loculated effusion but needs a different management approach. The present study evaluated the incidence and characteristics of neutrophilic loculated TPE and differentiated it from complicated PPE. Materials and Methods: Between 2009 and 2014, a cohort of patients with TPE was retrospectively reviewed in a South Korean referral hospital. Clinical, laboratory, computed tomography and pleural fluid findings of patients with neutrophilic loculated TPE were compared to those of patients with neutrophilic free-flowing TPE and complicated PPE, respectively. Results: Neutrophilic TPE was observed in 33 (10%) out of 344 patients with TPE. Of these, 10 (30%) patients exhibited loculation of the pleural fluid. These patients showed distinct pleural fluid characteristics. The classical pleural fluid biomarker levels were more intense than those observed in 23 patients with neutrophilic free-flowing TPE, but similar to those of 54 patients with complicated PPE. A high mycobacterial burden was observed in the pleural fluid, and favorable outcomes were achieved with antituberculosis drug administration alone. Nodular parenchymal lesions and pleural fluid adenosine deaminase levels were independent discriminators of neutrophilic loculated TPE and PPE. Conclusions: These results may be helpful to understand and manage patients with neutrophilic loculated TPE and differentiate them from patients with complicated PPE.</P>
Lee, Jaehee,Cha, Seung Ick,Park, Tae In,Park, Jae Yong,Jung, Tae Hoon,Kim, Chang Ho The Japanese Society of Internal Medicine 2011 Internal medicine Vol.50 No.5
<P>Cryptogenic organizing pneumonia (COP) generally responds well to corticosteroids with a favorable outcome. However, it can rapidly worsen and lead to respiratory failure that is refractory to corticosteroids. Adjunctive drugs have been used in refractory cases with various outcomes, but treatment experience is still lacking. We present a case of rapidly progressive COP accompanying air leak syndrome, which showed no prompt response to corticosteroids alone but gradual improvement with the addition of cyclosporine and macrolide. This case report supports the existing literature suggesting that an early therapeutic trial of this drug combination might be considered in COP patients whose condition worsens despite corticosteroid administration.</P>
( Jaehee Lee ),( Deok Heon Lee ),( Ji Eun Park ),( Yong Hoon Lee ),( Sun Ha Choi ),( Hyewon Seo ),( Seung Soo Yoo ),( Shin Yup Lee ),( Seung-ick Cha ),( Jae Yong Park ),( Chang Ho Kim ) 대한내과학회 2024 The Korean Journal of Internal Medicine Vol.39 No.2
Background/Aims: Epidermal growth factor receptor (EGFR) mutation is important in determining the treatment strategy for advanced lung cancer patients with malignant pleural effusion (MPE). Contrary to serum carcinoembryonic antigen (S-CEA) levels, the associations between pleural fluid CEA (PF-CEA) levels and EGFR mutation status as well as between PF-CEA levels and treatment efficacy have rarely been investigated in lung adenocarcinoma patients with MPE. Methods: This retrospective study enrolled lung adenocarcinoma patients with MPE and available PF-CEA levels and EGFR mutation results. The patients were categorized based on PF-CEA levels: < 10 ng/mL, 10-100 ng/mL, 100-500 ng/mL, and ≥ 500 ng/mL. The association between PF-CEA levels and EGFR mutation status as well as their therapeutic impact on overall survival was compared among the four groups. Results: This study included 188 patients. PF-CEA level was found to be an independent predictor of EGFR mutation but not S-CEA level. The EGFR mutation rates were higher as the PF-CEA levels increased, regardless of cytology results or sample types. Among EGFR-mutant lung adenocarcinoma patients receiving EGFR-tyrosine kinase inhibitor (TKI) treatment, those with high PF-CEA levels had significantly better survival outcomes than those with low PF-CEA levels. Conclusion: High PF-CEA levels were associated with high EGFR mutation rate and may lead to a favorable clinical outcome of EGFR-TKI treatment in EGFR-mutant lung adenocarcinoma patients with MPE. These findings highlight the importance of actively investigating EGFR mutation detection in patients with suspected MPE and elevated PF-CEA levels despite negative cytology results.
Lee Jaehee,Park Sunji,Park Ji Eun,Choi Sun Ha,Seo Hyewon,Yoo Seung Soo,Lee Shin Yup,Kim Yu Kyung,Cha Seung-Ick,Park Jae Yong,Park Tae In,Kim Chang Ho 대한의학회 2021 Journal of Korean medical science Vol.36 No.1
The cause of epithelioid granulomatous inflammation varies widely depending on the affected organ, geographic region, and whether the granulomas morphologically contain necrosis. Compared with other organs, the etiological distribution and morphological patterns of pleural epithelioid granulomas have rarely been investigated. We evaluated the final etiologies and morphological patterns of pleural epithelioid granulomatous inflammation in a tuberculosis (TB)-prevalent country. Of 83 patients with pleural granulomas, 50 (60.2%) had confirmed TB pleurisy (TB-P) and 29 (34.9%) had probable TB- P. Four patients (4.8%) with non-TB-P were diagnosed. With the exception of microbiological results, there was no significant difference in clinical characteristics and granuloma patterns between the confirmed TB-P and non-TB-P groups, or between patients with confirmed and probable TB-Ps. These findings suggest that most pleural granulomatous inflammation (95.2%) was attributable to TB-P in TB-endemic areas and that the granuloma patterns contributed little to the prediction of final diagnosis compared with other organs.
A Case of Metastatic Endobronchial Melanoma from an Unknown Primary Site
( Jaehee Lee ),( Shin Yup Lee ),( Seung Ick Cha ),( Byeong-cheol Ahn ),( Jae Yong Park ),( Tae Hoon Jung ),( Chang Ho Kim ) 대한결핵 및 호흡기학회 2012 Tuberculosis and Respiratory Diseases Vol.72 No.2
Melanoma can occur as a metastasis within subcutaneous tissue, lymph nodes, or viscera without a detectable primary tumor. Among patients with metastatic melanoma of unknown primary lesion, those with endobronchial metastasis are exceedingly rare. Herein we report a case of an endobronchial and pulmonary metastasis in a patient with melanoma originating from an unknown primary site. The patient without a previous history of melanoma presented with blood-tinged sputum. Fiberoptic bronchoscopy revealed a black polypoid tumor obstructing the posterior basal segmental bronchus of the right lower lobe. A final diagnosis of the malignant melanoma was made based on an immunohistochemical study of the bronchoscopic biopsy specimen. Skin, ophthalmic, oral, and nasal examinations failed to identify occult primary lesions. Subsequent evaluation including positron emission tomography/computed tomography scans did not uncover any abnormalities other than the metastatic pulmonary melanoma. We also describe the characteristic bronchoscopic features of melanoma.
Are Spinal GABAergic Elements Related to the Manifestation of Neuropathic Pain in Rat?
Jaehee Lee,Seung Keun Back,Eun Jeong Lim,Gyu Chong Cho,Myung Ah Kim,Hee Jin Kim,Min Hee Lee,Heung Sik Na 대한생리학회-대한약리학회 2010 The Korean Journal of Physiology & Pharmacology Vol.14 No.2
Impairment in spinal inhibition caused by quantitative alteration of GABAergic elements following peripheral nerve injury has been postulated to mediate neuropathic pain. In the present study, we tested whether neuropathic pain could be induced or reversed by pharmacologically modulating spinal GABAergic activity, and whether quantitative alteration of spinal GABAergic elements after peripheral nerve injury was related to the impairment of GABAergic inhibition or neuropathic pain. To these aims, we first analyzed the pain behaviors following the spinal administration of GABA antagonists (1Ռg bicuculline/rat and 5Ռg phaclofen/rat), agonists (1Ռg muscimol/rat and 0.5Ռg baclofen/rat) or GABA transporter (GAT) inhibitors (20Ռg NNC-711/rat and 1Ռg SNAP-5114/rat) into naïve or neuropathic animals. Then, using Western blotting, PCR or immunohistochemistry, we compared the quantities of spinal GABA, its synthesizing enzymes (GAD65, 67) and its receptors (GABA<sub>A</sub> and GABA<sub>B</sub>) and transporters (GAT-1, and -3) between two groups of rats with different severity of neuropathic pain following partial injury of tail-innervating nerves; the allodynic and non-allodynic groups. Intrathecal administration of GABA antagonists markedly lowered tail-withdrawal threshold in naïve animals, and GABA agonists or GAT inhibitors significantly attenuated neuropathic pain in nerve-injured animals. However, any quantitative changes in spinal GABAergic elements were not observed in both the allodynic and non-allodynic groups. These results suggest that although the impairment in spinal GABAergic inhibition may play a role in mediation of neuropathic pain, it is not accomplished by the quantitative change in spinal elements for GABAergic inhibition and therefore these elements are not related to the generation of neuropathic pain following peripheral nerve injury.
( Jaehee Mun ),( Seokyung Kim ),( Eun Ji Lee ),( Soo Jin Park ),( Joo-hyuk Son ),( Maria Lee ),( Tae-wook Kong ),( Hee Seung Kim ),( Jiheum Paek ),( Hyun Hoon Chung ),( Suk-joon Chang ),( Jae Weon Kim 대한산부인과학회 2020 대한산부인과학회 학술대회 Vol.106 No.-
Objective: Cremophor-free polymeric micelle formulation of paclitaxel (Genexol-PM) plus carboplatin (PM/C) has been reported to have a non-inferior effect with tolerable toxicities when compared to the standard paclitaxel plus carboplatin (P/C) in ovarian cancer. However, there is still a lack of evidence on the effect of an increased dose of paclitaxel in PM/C, especially, when compared to P/C and paclitaxel plus carboplatin with bevacizumab (P/C/B) in advanced high-grade serous ovarian cancer (HGSO). Thus, we performed a prospective cohort study on PM/C and compared the effect of PM/C with historical control of P/C and P/C/B in HGSO. Methods: We performed a prospective cohort study between October 2015 and June 2019. Patients aged 20 or more years with FIGO stage III-IV HGSO who received PM (260 mg/m<sup>2</sup>)/C (AUC 5) after primary debulking surgery (PDS) were enrolled. We collected clinico-pathologic data from a retrospective cohort when P (175 mg/m<sup>2</sup>)/C (AUC 5) or P (175 mg/m<sup>2</sup>)/C (AUC 5)/B (15 mg/kg) were used as adjuvant treatment after PDS during the same period. Results: A total of 104 patients were enrolled, and 17, 28, and 59 received P/C, P/C/B and, PM/C respectively (Table 1). Complete response was significantly highest in PM/C (29.4 vs. 39.3 vs. 61%, P=0.030; Table 1). Progression-free survival was longest in PM/C (Figure 1) and multivariate analysis showed that gross residual tumor after PDS and P/C were poor prognostic factors (adjusted hazard ratios, 2.415 and 2.751; 95% confidence intervals, 1.172-4.976 and 1.214-6.236; Table 2). Even after adjustment of the patient pool to those with no gross residual tumor after PDS, multivariate analysis still showed that P/C lowered the survival curve (adjusted hazard ratio, 3.342; 95% confidence interval, 1.143-9.777; Table 2). Conclusion: This interim analysis showed that PM/C had a comparable effect to P/C/B for stage III-IV HGSO patients who received optimal cytoreduction during PDS.